var data={"title":"Cysteamine (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cysteamine (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/526210?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cysteamine-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cysteamine (systemic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=cysteamine-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cysteamine (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15510916\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cystagon;</li>\n      <li>Procysbi</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50293038\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Procysbi</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15510919\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticystine Agent;</li>\n      <li>\n        Urinary Tract Product</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15510957\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nephropathic cystinosis:</b> Oral: <b>Note:</b> Begin therapy as soon as the diagnosis of nephropathic cystinosis has been confirmed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Immediate release (Cystagon):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initial:</i> Initiate therapy with <sup>1</sup>/<sub>6</sub> to <sup>1</sup>/<sub>4</sub> of maintenance dose; titrate slowly upward over 4 to 6 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance dose:</i> 500 mg 4 times daily; maximum dose: 1.95 <b>g</b>/m<sup>2</sup>/day or 90 mg/kg/<b>day</b> (off-label dose) (Gahl 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dosage adjustment:</i> Dosage adjustments should be made based on target WBC cystine concentrations (&lt;1 nmol/half-cystine/mg protein). If the patient is tolerating therapy, the target WBC cystine level should be &lt;1 nmol/half-cystine/mg protein; patients with poorer tolerability may still receive benefit when WBC cystine levels are kept at &lt;2 nmol/half-cystine/mg protein. If the WBC cystine level is &gt;1 nmol/half-cystine/mg protein, confirm that the patient is compliant with regard to administration (including proper dosing interval and relationship between administration of medication and food) and the timing between last dose and blood draw.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Missed doses:</i> Administer missed dose as soon as possible. If the next scheduled dose is due in &lt;2 hours, skip the missed dose and resume the regular dosing schedule. Do not take 2 doses at one time to make up for the missed dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Switching from cysteamine hydrochloride or phosphocysteamine solutions:</i> Initiate immediate release cysteamine bitartrate at an equimolar dose to the cysteamine hydrochloride or phosphocysteamine dose; monitor WBC cystine concentrations 2 weeks after the switch, then every 3 months thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Delayed release (Procysbi): </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initial:</i> 0.2 to 0.3 <b>g</b>/m<sup>2</sup>/day divided every 12 hours; titrate slowly upward over 4 to 6 weeks to target maintenance dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance:</i> 1.3 <b>g</b>/m<sup>2</sup>/day divided every 12 hours; may increase as needed in 10% increments; maximum daily dose: 1.95 <b>g</b>/m<sup>2</sup>/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Missed doses:</i> Administer missed dose as soon as possible up to 8 hours after the scheduled dose. If the next scheduled dose is due in &lt;4 hours, skip the missed dose and resume the regular dosing schedule. Do not take 2 doses at one time to make up for the missed dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Switching from immediate release cysteamine bitartrate to delayed release cysteamine bitartrate:</i> Initiate delayed release cysteamine bitartrate at a total daily dose equal to the total daily dose of the immediate release formulation; divide the total daily dose in half and administer every 12 hours. If patient is unable to tolerate initial dose, decrease dose and gradually increase to maintenance dose. Monitor WBC cystine levels 2 weeks after the switch, then quarterly for 6 months, then a minimum of 2 times annually thereafter. Titrate the dose as needed to achieve target WBC cystine concentrations (maximum dose: 1.95 g/m<sup>2</sup>/day).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15510956\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=cysteamine-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cysteamine (systemic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Begin therapy as soon as the diagnosis of nephropathic cystinosis has been confirmed. Dosing presented as cysteamine base; may be presented as <b>g</b>/m<sup>2</sup> or mg/kg; verify dosage unit for calculations; extra precautions should be taken.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nephropathic cystinosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Immediate release (Cystagon):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer&rsquo;s labeling: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Initial dose:</i> Infants, Children, and Adolescents: To avoid intolerance, initiate therapy with <sup>1</sup>/<sub>6</sub> to <sup>1</sup>/<sub>4</sub> of maintenance dose (see below for maintenance doses); titrate slowly upward over 4 to 6 weeks. Dosage adjustments should be made based on target WBC cystine levels.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Maintenance dose:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">BSA-directed dosing: Oral: 1.3 <b>g</b>/m<sup>2</sup>/day divided into 4 doses up to 2,000 mg/day (500 mg 4 times daily); maximum daily dose: 1.95 <b>g</b>/m<sup>2</sup>/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Weight-directed dosing: Approximate dose of 1.3 <b>g</b>/m<sup>2</sup>/day; may increase if needed to achieve target WBC cysteine concentrations; maximum daily dose: 1.95 <b>g</b>/m<sup>2</sup>/<b>day</b>: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:16em;\">&lt;5 kg: 100 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:16em;\">5 to &lt;9.5 kg: 150 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:16em;\">9.5 to &lt;14 kg: 200 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:16em;\">14 to &lt;18.5 kg: 250 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:16em;\">18.5 to &lt;23 kg: 300 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:16em;\">23 to &lt;32 kg: 350 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:16em;\">32 to &lt;41 kg: 400 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:16em;\">41 to &le;50 kg: 450 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:16em;\">&gt;50 kg: 500 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Alternate dosing: Infants, Children, and Adolescents: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Weight-based dosing: Oral: Initial: 10 mg/kg/day divided into 4 doses daily; increase in 10 mg/kg/day increments until maintenance dose of 60 to 90 mg/kg/day divided into 4 doses daily is achieved (Gahl 2002); maximum daily dose: 1.95 <b>g</b>/m<sup>2</sup>/<b>day</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Weight-directed dosing: Oral: Based on a population pharmacokinetic model (n=69, mean age: 12.5 years, range: 0.4 to 36 years) (Bouazza 2011); maximum daily dose: 1.95 <b>g</b>/m<sup>2</sup>/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:16em;\">10 to &lt;17 kg: 20 mg/kg/dose every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:16em;\">17 to &lt;25 kg: 17.5 mg/kg/dose every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:16em;\">25 to &lt;40 kg: 15 mg/kg/dose every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:16em;\">40 to 70 kg: 12.5 mg/kg/dose every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Missed doses:</i> Administer missed dose as soon as possible. If the next scheduled dose is due in &lt;2 hours, skip the missed dose and resume the regular dosing schedule. Do not take 2 doses at one time to make up for the missed dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Switching from cysteamine hydrochloride or phosphocysteamine solutions to cysteamine bitartrate:</i> Initiate immediate release cysteamine bitartrate at an equimolar dose to the cysteamine hydrochloride or phosphocysteamine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Delayed release (Procysbi):</i></b>Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial dose:</i> Oral: Initiate therapy with <sup>1</sup>/<sub>6</sub> to <sup>1</sup>/<sub>4</sub> of maintenance target dose and round as appropriate based on available dosage forms:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;6 kg: 25 to 50 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">6 to &lt;11 kg: 50 to 75 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">11 to &lt;16 kg: 75 to 100 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">16 to &lt;21 kg: 100 to 125 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">21 to &lt;26 kg: 100 to 150 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">26 to &lt;31 kg: 125 to 175 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">31 to &lt;41 kg: 125 to 200 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">41 to &lt;51 kg: 150 to 225 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;51 kg: 175 to 250 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Titration: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &lt;6 years of age: Gradually increase dose in 10% increments every 2 weeks (or longer) until target WBC cystine concentration or maintenance dose is achieved. If the therapeutic target WBC cystine concentration is achieved below the recommended maintenance dose, discontinue dose escalation and use dose as the maintenance dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;6 years of age and Adolescents: Gradually increase dose over 4 to 6 weeks until maintenance dose is achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Maintenance dose:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">BSA-directed dosing: Oral: 1.3 <b>g</b>/m<sup>2</sup>/day divided every 12 hours; may increase as needed in 10% increments to achieve target WBC cystine concentrations; maximum daily dose: 1.95 <b>g</b>/m<sup>2</sup>/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-directed dosing: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;6 kg: 200 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">6 to &lt;11 kg: 300 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">11 to &lt;16 kg: 400 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">16 to &lt;21 kg: 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">21 to &lt;26 kg: 600 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">26 to &lt;31 kg: 700 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">31 to &lt;41 kg: 800 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">41 to &lt;51 kg: 900 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;51 kg: 1,000 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Missed doses:</i> Administer missed dose as soon as possible up to 8 hours after the scheduled dose. If the next scheduled dose is due in &lt;4 hours, skip the missed dose and resume the regular dosing schedule. Do not take 2 doses at one time to make up for the missed dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Switching from immediate release cysteamine bitartrate to delayed release cysteamine bitartrate:</i> Initiate delayed release cysteamine bitartrate at a total daily dose equal to the total daily dose of the immediate release formulation and divide into 2 doses per day every 12 hours. If patient is unable to tolerate initial dose, decrease dose and gradually increase to maintenance dose. Monitor WBC cystine levels 2 weeks after the switch, then quarterly for 6 months, then a minimum of 2 times annually thereafter. Titrate the dose as needed to achieve target WBC cystine concentrations (maximum dose: 1.95 g/m<sup>2</sup>/day).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15510958\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15516523\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15516524\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20798312\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal symptoms, (GI bleeding, nausea, vomiting, anorexia, or abdominal pain), transient skin rashes, CNS symptoms (eg, seizures, lethargy, somnolence, depression, encephalopathy):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release: Infants, Children, Adolescents, and Adults:</i> Temporarily discontinue therapy. Reinitiate at a lower dose; titrate slowly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Delayed release:</i> <i>Children, Adolescents, and Adults:</i> Decrease dose. May temporarily discontinue therapy and reinitiate at a lower dose; titrate slowly. Some patients may be unable to achieve their therapeutic target.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe skin rashes (eg, erythema multiforme bullosa, toxic epidermal necrolysis): Permanently discontinue therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15510970\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cystagon: 50 mg, 150 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Delayed Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Procysbi: 25 mg, 75 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15510918\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15510960\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Immediate release:</i> In patients &lt;6 years of age or those unable to swallow capsules, sprinkle capsule contents over food or mix in juice (Gahl 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Delayed release:</i> Swallow capsules whole with fruit juice (except grapefruit juice) or water; do not crush or chew. Administer &ge;30 minutes before and &ge;2 hours after meals; if necessary, patients may eat only a small amount (~4 ounces or <sup>1</sup>/<sub>2</sub> cup) of food between 1 hour before and 1 hour after administration. Avoid high-fat food close to time of dose. Administer at least 1 hour before or 1 hour after medications containing bicarbonate or carbonate. Maintain consistency of administration with regard to food. Alternatively, may sprinkle intact granules on a small amount of applesauce or berry jelly (&le;4 ounces, as small as necessary to be consumed in one feeding) or add to ~4 ounces of fruit juice (except grapefruit juice) and mix gently after adding to food or juice. Administer within 30 minutes of adding to food or drink; do not save mixture for later use or chew granules.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrostomy tube: In patients with a 14 French or larger gastrostomy tube, intact granules may be mixed with ~4 ounces of strained applesauce. In children &le;25 kg (starting at a dose of 1 or 2 capsules), a minimum of 1 ounce of strained applesauce may be used. Draw mixture into a syringe, keep the feeding tube horizontal, apply rapid and steady syringe pressure (10 mL/10 seconds), and administer within 30 minutes of mixing; do not save mixture for later use. Fill another syringe with &ge;10 mL fruit juice (except grapefruit juice) or water, swirl gently, and flush the tube.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15510923\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Nephropathic cystinosis: </b>Management of nephropathic cystinosis (Immediate release [Cystagon]: FDA approved in all ages; delayed release [Procysbi]: FDA approves in ages &ge;1 year and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45807257\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Mercaptamine [multiple international markets] and also a synonym for cysteamine (systemic) may be confused with mercaptopurine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15510931\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Immediate release as reported in children. Delayed release as reported in children, adolescents, and adults.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Lethargy (immediate release: 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (immediate release: 35%; delayed release: 19%), anorexia (immediate release: 31%; delayed release: 2%), diarrhea (immediate release: 16%; delayed release: &gt;5%), nausea (delayed release: 16%; immediate release: &le;5%), abdominal discomfort (delayed release: &le;14%), abdominal pain (&le;14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (immediate release: 22%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (immediate release: &le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (5% to 9%), fatigue (delayed release: &gt;5%), abnormality in thinking (immediate release: &le;5%), ataxia (immediate release: &le;5%), brain disease (immediate release: &le;5%), confusion (immediate release: &le;5%), depression (immediate release: &le;5%), dizziness (&le;5%), drowsiness (immediate release: &le;5%), emotional lability (immediate release: &le;5%), hallucination (immediate release: &le;5%), jitteriness (immediate release: &le;5%), nervousness (immediate release: &le;5%), nightmares (immediate release: &le;5%), seizure (immediate release: &le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (&gt;5% to 7%), abnormal skin odor (delayed release: &gt;5%), urticaria (immediate release: &le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Dehydration (immediate release: &le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (immediate release: &le;5%), duodenitis (immediate release: &le;5%), dyspepsia (immediate release: &le;5%), gastroenteritis (immediate release: &le;5%), gastrointestinal hemorrhage (immediate release: &le;5%), gastrointestinal ulcer (immediate release: &le;5%), halitosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (immediate release: &le;5%), leukopenia (immediate release: &le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal hepatic function tests (immediate release: &le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Hyperkinesia (immediate release: &le;5%), tremor (immediate release: &le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Hearing loss (immediate release: &le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Interstitial nephritis (immediate release: &le;5%), renal failure (immediate release: &le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Electrolyte disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Viral gastroenteritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Atrophic striae, connective tissue disorder (Ehlers Danlos-like syndrome), erythema multiforme, fragile skin, genu valgum, intracranial hypertension (benign), joint hyperextension, leg pain, molluscoid pseudotumors, osteopenia, papilledema, pseudotumor cerebri, scoliosis, skin lesion, toxic epidermal necrolysis, vertebral compression fracture</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15510928\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cysteamine, penicillamine, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15510929\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS symptoms: Depression, lethargy, seizures, somnolence, and encephalopathy have been reported in patients receiving the immediate-release formulation; may also occur due to cystinosis not treated with cysteamine. Treatment interruption or dosage reduction may be required in patients with severe or persistent/progressive symptoms. Patients should use caution when driving or operating heavy machinery until the effects are known.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic: Skin rashes (including erythema multiforme bullosa and toxic epidermal necrolysis) have occurred in patients receiving the immediate-release formulation. In patients who develop severe skin rashes, permanently discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ehlers-Danlos-like syndrome: Ehlers-Danlos-like clinical findings, including skin lesions (eg, molluscoid pseudotumors, skin striae), bone lesions (osteopenia, compression fractures, scoliosis, and genu valgum), leg pain, and joint hyperextension, have occurred with high doses of the immediate-release formulation. A fatality (with serious skin lesions on immediate-release formulation) has been reported. Monitor for development of skin or bone lesions; interruption of therapy and subsequent dosage reduction with slow titration to therapeutic dose may be required if these symptoms develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal symptoms: Gastrointestinal ulcers and bleeding, nausea, vomiting, anorexia, and abdominal pain have been reported in patients receiving the immediate-release formulation. GI symptoms are most commonly seen during the initiation of therapy. If severe symptoms occur, consider a dosage reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic: May cause reversible leukopenia. Monitor WBCs; if leukopenia occurs, consider a dosage reduction or discontinuing the drug until values return to normal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic: May cause elevated alkaline phosphatase levels. Monitor alkaline phosphatase; if elevation occurs, consider a dosage reduction or discontinuing the drug until values return to normal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intracranial hypertension/papilledema: Benign intracranial hypertension (pseudotumor cerebri [PTC]) and/or papilledema have been reported in patients receiving the immediate-release formulation; monitor for signs and symptoms of PTC (eg, headache, tinnitus, dizziness, nausea, diplopia, blurred vision, loss of vision, pain behind the eye or with eye movement). If symptoms persist, interrupt dosing or decrease the dose and refer to an ophthalmologist. If diagnosis is confirmed, permanently discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Nephropathic cystinosis: Initiate therapy as soon as the diagnosis has been confirmed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15510936\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15510937\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=87033&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of Cysteamine (Systemic). Alcohol (Ethyl) may diminish the therapeutic effect of Cysteamine (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May diminish the therapeutic effect of Cysteamine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May diminish the therapeutic effect of Cysteamine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May diminish the therapeutic effect of Cysteamine (Systemic).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20797463\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Concurrent ingestion of food and the delayed release formulation of cysteamine can reduce the systemic exposure of cysteamine. Management: Administer &ge;30 minutes before and &ge;2 hours after meals; if necessary, patients may eat only a small amount (~4 ounces or <sup>1</sup>/<sub>2</sub> cup) of food between 1 hour before and 1 hour after administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15510925\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15510927\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if cysteamine is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20798235\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Delayed release: Do not administer with grapefruit juice. Take &ge;30 minutes before and &ge;2 hours after meals; if necessary, may eat only a small amount (~4 ounces or <sup>1</sup>/<sub>2</sub> cup) of food between 1 hour before and 1 hour after administration. Avoid high fat food close to time of dose.  Avoid alcohol intake during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15510962\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>General:</i> Monitor blood counts and LFTs (including alkaline phosphatase) during therapy; monitor for signs and symptoms of gastrointestinal ulceration and bleeding, skin and bone lesions, skin rashes, and pseudotumor cerebri. Perform periodic ophthalmic examinations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Cysteamine-naive patients starting on the immediate-release capsule formulation:</i> Monitor WBC cystine after reaching maintenance dose, then a minimum of every 3 months thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Cysteamine-naive patients starting directly on the delayed-release formulation:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &lt;6 years of age: Monitor WBC cystine 2 weeks after treatment initiation and continue monitoring during dosage titration period until the therapeutic target WBC cystine concentration is achieved. Once the therapeutic target is achieved, monitor monthly for 3 months, then every 3 months for 1 year, and then a minimum of twice annually thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;6 years of age, Adolescents, and Adults: Monitor WBC cystine after reaching maintenance dose, then monthly for 3 months, then every 3 months for 1 year, then a minimum of twice annually thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Switching from cysteamine hydrochloride or phosphocysteamine solutions to cysteamine bitartrate:</i> Monitor WBC cystine concentrations 2 weeks after the switch, then every 3 months thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Patients switching to the delayed-release formulation from the immediate-release formulation:</i> Monitor WBC cystine concentrations 2 weeks after the switch; continue monitoring if further dosage adjustment is needed. Once therapeutic target WBC cystine concentration is achieved, monitor every 3 months for 6 months, and then a minimum of twice annually thereafter.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15510946\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Normal WBC cystine ranges and therapeutic target concentrations for cystine depletion may vary based on the assay method used. WBC cystine values obtained from using different assay methods may not be interchangeable. Check with institution laboratory to determine assay method used and associated concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">WBC (leukocyte) cystine (using the mixed leukocyte assay):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Normal individual: WBC cystine: &lt;0.2 nmol/half-cystine/mg protein</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cystinosis target: WBC cystine: &lt;1 nmol/half-cystine/mg protein (if poor tolerability to cysteamine, may still benefit from leukocyte cystine levels &lt;2 nmol/half-cystine/mg protein)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Timing of samples (WBC cystine):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release:</i> 5 to 6 hours postdose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Delayed release:</i> 12 hours postdose (immediately prior to next dose)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15510944\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Reacts with cystine within the lysosome to convert it to cysteine and to a cysteine-cysteamine mixed disulfide, both of which can then exit the lysosome in patients with cystinosis, an inherited defect of lysosomal transport</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15510947\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Immediate release: 1.8 &plusmn; 0.8 hours; Delayed release: 3 to 3.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Immediate release: 6 hours; Delayed release: ~12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Immediate release: Pediatric patients: 156 L; however variability has been reported 180 &plusmn; 112 L (Langman 2012); reported data adjusted for weight: Children and Adolescents 3 to 15 years: Median 9.9 L/kg (range: 2.7 to 32.3 L/kg) (Belldina 2003); Adults: ~198 L; Delayed release: Children and Adolescents: 356 &plusmn; 376 L (Langman 2012); Adults: ~382 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~52%, predominantly to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Immediate release: Children and Adolescents: 1.5 &plusmn; 0.4 hours (Langman 2012); Adults: 1.5 hours; Delayed release: Children and Adolescents: 4.2 &plusmn; 6.8 hours (Langman 2012); Adults: 4.2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Immediate release: Children and Adolescents: Mean range: 1.2 to 1.4 hours (range 1 to 2 hours) (Belldina 2003; Langman 2012); Adults: ~1.4 hours; Delayed release: 3 to 4.6 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570458\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Procysbi Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (60): $6,629.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (250): $27,621.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Cystagon Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $43.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (100): $127.95</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059515\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cystagon (AT, AU, BB, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HR, HU, IE, IS, IT, LT, MT, NL, NO, PL, PT, RO, RU, SE, SI, SK, TR, TW);</li>\n      <li>Nicystagon (JP)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cysteamine-systemic-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Belldina EB, Huang MY, Schneider JA, et al. Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients. <i>Br J Clin Pharmacol</i>. 2003;56(5):520-525.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cysteamine-systemic-drug-information/abstract-text/14651726/pubmed\" target=\"_blank\" id=\"14651726\">14651726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bouazza N, Tr&eacute;luyer JM, Ottolenghi C, et al. Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients.<i> Orphanet J Rare Dis</i>. 2011;6:86. doi: 10.1186/1750-1172-6-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cysteamine-systemic-drug-information/abstract-text/22195601/pubmed\" target=\"_blank\" id=\"22195601\">22195601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cystagon (cysteamine) [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dohil R, Fidler M, Gangoiti JA, et al, &quot;Twice-Daily Cysteamine Bitartrate Therapy for Children With Cystinosis,&quot; <i>J Pediatr</i>, 2010, 156(1):71-75.e1-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cysteamine-systemic-drug-information/abstract-text/19775699/pubmed\" target=\"_blank\" id=\"19775699\">19775699</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gahl WA, Thoene JG, and Schneider JA, &ldquo;Cystinosis,&rdquo; <i>N Engl J Med</i>, 2002, 347(2):111-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cysteamine-systemic-drug-information/abstract-text/12110740/pubmed\" target=\"_blank\" id=\"12110740\">12110740</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Langman CB, Greenbaum LA, Sarwal M, et al, &quot;A Randomized Controlled Crossover Trial With Delayed-Release Cysteamine Bitartrate in Nephropathic Cystinosis: Effectiveness on White Blood Cell Cystine Levels and Comparison of Safety,&quot; <i>Clin J Am Soc Nephrol</i>, 2012, 7(7):1112-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cysteamine-systemic-drug-information/abstract-text/22554716/pubmed\" target=\"_blank\" id=\"22554716\">22554716</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Procysbi (cysteamine) [prescribing information]. Lake Forest, IL: Horizon Pharma USA; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cysteamine-systemic-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 87033 Version 74.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F15510916\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50293038\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F15510919\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F15510957\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F15510956\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F15510958\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15516523\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15516524\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F20798312\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F15510970\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F15510918\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F15510960\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F15510923\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F45807257\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F15510931\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F15510928\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F15510929\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F15510936\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F15510937\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F20797463\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F15510925\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F15510927\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F20798235\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F15510962\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F15510946\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F15510944\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F15510947\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570458\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059515\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/87033|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cysteamine-systemic-patient-drug-information\" class=\"drug drug_patient\">Cysteamine (systemic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=cysteamine-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Cysteamine (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}